Alzheimer’s Association Calls on Biogen to Lower Aduhelm’s Price

The Alzheimer’s Association is the latest group to call on Biogen to lower the price of Aduhelm, its controversial Alzheimer’s disease drug. This is a surprising move as the association has historically been reluctant to enter the pricing debate.

“Pharma’s fiercest critics here — many of whom have blasted patient advocacy groups for not being more involved in the drug pricing debate — celebrated the Alzheimer’s Association’s audacity, especially as it risked being blackballed by its pharma funders. The statement made it clear that Biogen, as one crisis communications expert put it, “can’t afford to alienate its biggest cheerleader.”’ Read more here.

(Source: Nicholas Florko, STAT News, 7/6/21)